Leon Pharm

Leon-Nanodrugs is a Munich-based nanotechnology company specializing in the reformulation of poorly soluble active pharmaceutical ingredients (APIs) to improve their bioavailability and efficacy. The company's core technology is the proprietary Micro-Jet Reactor (MJR), a continuous bottom-up process that produces stable, high-quality nanoparticles with precise size control. Leon-Nanodrugs focuses on developing its own pipeline of value-added generics via the 505(b)(2) pathway and collaborating with pharmaceutical partners to enhance their drug candidates. Key programs include nano-formulations of propofol, amiodarone, and cyclosporine, as well as expanding into lipid nanoparticle (LNP) delivery for genetic medicines. The company aims to provide faster onset of action, reduced side effects, and improved patient compliance through its advanced drug delivery solutions.